CDK4 and colorectal carcinoma: Bioluminescent imaging (panel A) and analysis in GraphPad Prism (panel B) revealed that CRC cells are sensitive to palbociclib (IC50 = ~8 μM), providing a rationale to test the CDK4/6-targeting miR-6883 as a potential therapeutic agent for this disease.